

FOR IMMEDIATE RELEASE

VIDIUM ANIMAL HEALTH® TO PRESENT *BRINGING PRECISION MEDICINE TO PETS* AT BIOTECH SHOWCASE™ 2022

PHOENIX, Ariz. (January 7, 2022) — Vidium Animal Health® announced that it is presenting virtually at the Biotech Showcase™ 2022 conference, January 10-19.

Presenter David Haworth, DVM, PhD, Vidium president and co-founder, will discuss how Vidium is changing the way veterinarians approach cancer care in dogs. In recent years, human oncology has been transformed by precision medicine, which is the science of using drugs specifically targeted against a tumor's mutations. By opening the use of personalized, precision medicine to the veterinary marketplace, Vidium is helping advance the care of dogs with cancer.

Vidium's advanced diagnostics leverage the latest science available to provide critical information about a dog's cancer. The company's best-in-class genomic diagnostic test, SearchLight DNA™, uses next-generation sequencing to identify important mutations in 120 relevant cancer genes. By providing a better understanding of a patient's cancer, Vidium is helping to guide veterinary teams through the challenges and complexities of managing a patient's cancer diagnosis.

"A disproportionately higher percentage of dogs than humans will be diagnosed with cancer this year in the US," notes Haworth. "There is an incredible need in animal health to combat canine cancer in new and more effective ways. Through our suite of advanced cancer diagnostic tools, Vidium is helping veterinary teams improve the standard of care in canine oncology."

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during one of the industry's largest gatherings and busiest weeks.

ABOUT BIOTECH SHOWCASE

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet

with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 14th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and the broader life sciences industry.

ABOUT VIDIUM ANIMAL HEALTH

Vidium Animal Health, a subsidiary of Translational Genomics Research Institute (TGen), is committed to advancing the understanding of disease to give pets the fullest lives possible. The company provides diagnostic tests to veterinary oncologists, general practitioners, and pet parents, and is passionate about unravelling the genetic components of common and complex diseases, including cancer. Vidium was built on a foundation of unimpeachable science and is led by a knowledgeable and experienced team with deep veterinary and clinical genomic roots. For more information, visit: vidiumah.com. Follow Vidium on [Facebook](#), [LinkedIn](#), and [Twitter @vidiumah](#).

ABOUT TGEN, AN AFFILIATE OF CITY OF HOPE

Based in Phoenix, Arizona, Translational Genomics Research Institute (TGen) is a nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes, and other life-threatening diseases: CityofHope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes, and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through the efficiency and effectiveness of the translational process. For more information, visit: tgen.org. Follow TGen on [Facebook](#), [LinkedIn](#), and [Twitter @TGen](#).

#

Contact: David Haworth, DVM, PhD
president and co-founder, Vidium Animal Health
dhaworth@vidiumah.com
mobile: 480.318.1931